BG Medicine Posts 17 Percent Drop in Q1 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $739,000, down 17 percent from $888,000 in the first quarter of 2013.

Sales of the company's BGM-Galectin-3 heart failure test accounted for all of its revenues. It posted no service revenues in the quarter, compared to $68,000 in service revenues in Q1 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.